The platform is designed to reduce barriers to care for patients with COVID-19.
Ada Health Inc., a global digital health company, announced the launch of its first digital condition-based care journey, designed to help people understand if they meet current criteria for progression to severe COVID-19 and connect with a health care provider for evaluation of their COVID symptoms and treatment options.
Almost 200 million Americans have one or more risk factors, such as being 50 or older, being pregnant, a smoker, overweight or having certain common medical conditions–such as diabetes or asthma that puts them at high risk of progression to severe COVID. However, many people are not aware of their increased risk. COVID remains the third leading cause of death in the US, currently causing an average of over 400 deaths a day.
The COVID-19 Care Journey is an online platform operated by Ada and developed in partnership with Pfizer. The platform hosts an independent telehealth and ePharmacy provider option. The care journey allows users to:
Continue reading this story here.
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
February 4th 2025Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.